Drugs Made In America Acquisition Corp.
IPO Proceeds, $M | $200.00M |
---|---|
IPO Date | Jan 28, 2025 |
CEO | Lynn Stockwell |
Left Lead | Clear Street |
IPO Cash in Trust | 100.5% |
SPAC Tenor | 15+(2*3) |
IPO Sector |
Healthcare
Pharmaceutical industry |
IPO Geography | Global |
Target Company | TBD |
Deal Announced | TBD |
Deal Size, $M | TBD |
Deal Sector | TBD |
Deal Geography | TBD |
SEC Filings | www.sec.gov |
Approval Vote | TBD |
Amendment Vote | TBD |
Price | |
---|---|
Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Drugs Made In America Acquisition Corp.:
- Structure and cap table
- 5 directors & officers
- 6 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Lynn Stockwell | 68 | Chief Executive Officer and Executive Chair of the Board |
Glenn Worman | 65 | Chief Financial Officer |
Catherine Do | 45 | Director |
G. Sridhar Prasad | 61 | Director |
Myron W. Shulgan | 78 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Clear Street | BR | 20,000,000 | units |
20,000,000 | units | ||
Up-Front UW fee | 0.50 | % | |
Deferred UW fee |
3.00 | % |
Sign in to view more advisor data.
Filings
Aug 1, 2024 | Initial S-1 |
Sep 27, 2024 |
Amended S-1
Sign In to view filing content. |
Nov 7, 2024 |
Amended S-1
Sign In to view filing content. |
Jan 14, 2025 |
POS AM Amended S-1
Sign In to view filing content. |
Jan 27, 2025 |
PR announcing pricing of $200mm IPO
Sign In to view filing content. |
Jan 29, 2025 | 424B4 IPO Prospectus |